Jennifer Bailey-Lundberg, Associate Professor of Pathology, Microbiology and Immunology at University of Nebraska Medical Center, shared on X:
“New preprint with Kathy Delgiorno: KRAS-MAPK signaling sustains CD73 expression in PDAC. Daraxonrasib + quemliclustat enhaces tumor control and reshapes the tumor immune landscape. Led by Khadija! Congrats to Urvinder Kaur, Katherine Ankenbauer and the team!”
Title: Oncogenic KRAS-MAPK signaling sustains a CD73 dependent therapeutic vulnerability in pancreatic cancer
Authors: Khadija Turabi, Urvinder Kaur Sardarni, Katherine E. Ankenbauer, Sabrina M. Torbit, Vidhi Chandra, Christopher P. Taranto, Shwetapadma Dash, Audrey Meade, Amelia T. Cephas, Kelsey A. Klute, Marina Pasca di Magliano, Florencia McAllister, Thomas McFall, Kathleen E DelGiorno, Jennifer M. Bailey-Lundberg
You may also be interested in: Phase 3 RASolute 309 Trial Begins: RASONQUE Plus Zoldonrasib in First-Line RAS G12D PDAC
